Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
-list item one, The purpose of this study is to evaluate the overall response rate of
belotecan (CKD-602) in recurrent or progressive carcinoma of uterine cervix